BiotechTube

decitabine Induction Chemotherapy + Induction Chemotherapy

Phase 2Withdrawn
1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Acute Myelogenous Leukemia (AML)

Conditions

Acute Myelogenous Leukemia (AML)

Trial Timeline

Jun 1, 2010 → —

NCT ID
NCT00943553

About decitabine Induction Chemotherapy + Induction Chemotherapy

decitabine Induction Chemotherapy + Induction Chemotherapy is a phase 2 stage product being developed by Eisai for Acute Myelogenous Leukemia (AML). The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00943553. Target conditions include Acute Myelogenous Leukemia (AML).

What happened to similar drugs?

20 of 20 similar drugs in Acute Myelogenous Leukemia (AML) were approved

Approved (20) Terminated (4) Active (0)
✅high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibeYuhanApproved
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
✅PrasugrelDaiichi SankyoApproved
✅30-day DAPT + Guideline-directed therapyDaiichi SankyoApproved
✅Sitafloxacin + Moxifloxacin HydrochlorideDaiichi SankyoApproved
✅micafungin + posaconazoleAstellas PharmaApproved
✅Selbex + SelbexEisaiApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00943553Phase 2Withdrawn

Competing Products

20 competing products in Acute Myelogenous Leukemia (AML)

See all competitors
ProductCompanyStageHype Score
mRNA-1403ModernaPhase 2
0
mRNA-1403ModernaPhase 3
0
DFN-02Dr. Reddy's LaboratoriesPhase 3
37
DFN-15 (Celecoxib Oral Solution) 62.5 mg + DFN-15 (Celecoxib Oral Solution) 125 mg + DFN-15 (Celecoxib Oral Solution) 250 mg + PlaceboDr. Reddy's LaboratoriesPhase 2
32
AFM28AffimedPhase 1
11
TRV130 1.5 mg + TRV130 3 mg + TRV130 4.5 mg + Morphine 10 mg + PlaceboTrevenaPhase 1
19
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + PlaceboTrevenaPhase 2
25
Oliceridine + Placebo + MorphineTrevenaPhase 3
30
Oliceridine + Placebo + MorphineTrevenaPhase 3
30
TRV130TrevenaPhase 3
30
TRV130 + Morphine + PlaceboTrevenaPhase 2
25
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimenCSPC Pharmaceutical Group LimitedPhase 2
42
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T CellsCSPC Pharmaceutical Group LimitedPhase 2
39
SPT-07A injectionSinopharmPhase 3
36
PRGN-3006 T CellsPrecigenPhase 1
27
BisantreneRace OncologyPhase 2
29
Bisantrene Dihydrochloride (high dose) + Bisantrene Dihydrochloride (low dose) + Cytarabine Hydrochloride + Decitabine and cedazuridineRace OncologyPhase 1
15
Bisantrene + Fludarabine + ClofarabineRace OncologyPhase 2
25
ZN-d5 ZN-c3 + ZN-c3Zentalis PharmaceuticalsPhase 1/2
14
ZN-d5Zentalis PharmaceuticalsPhase 1
19